A Double-Blind, Placebo-Controlled Trial to Assess the Efficacy of Quetiapine Fumarate XR in Very Heavy-Drinking Alcohol-Dependent Patients

Background:  Despite advances in developing medications to treat alcohol dependence, few such medications have been approved by the Food and Drug Administration. Identified molecular targets are encouraging and can lead to the development and testing of new compounds. Atypical antipsychotic medicati...

Full description

Saved in:
Bibliographic Details
Published in:Alcoholism, clinical and experimental research clinical and experimental research, 2012-03, Vol.36 (3), p.406-416
Main Authors: Litten, Raye Z., Fertig, Joanne B., Falk, Daniel E., Ryan, Megan L., Mattson, Margaret E., Collins, Joseph F., Murtaugh, Cristin, Ciraulo, Domenic, Green, Alan I., Johnson, Bankole, Pettinati, Helen, Swift, Robert, Afshar, Maryam, Brunette, Mary F., Tiouririne, Nassima A.-D., Kampman, Kyle, Stout, Robert
Format: Article
Language:English
Subjects:
Addictive behaviors
Adolescent
Adult
Adult and adolescent clinical studies
Alcohol
Alcohol Dependence
Alcohol Drinking - drug therapy
Alcohol Use Disorder
Alcoholism
Alcoholism - drug therapy
Alcoholism and acute alcohol poisoning
Antipsychotic Agents - administration & dosage
Antipsychotic Agents - adverse effects
Antipsychotic Agents - therapeutic use
Anxiety - complications
Anxiety - drug therapy
Biological and medical sciences
Delayed-Action Preparations - therapeutic use
Depression - complications
Depression - drug therapy
Dibenzothiazepines - administration & dosage
Dibenzothiazepines - adverse effects
Dibenzothiazepines - therapeutic use
Double-Blind Method
Drug therapy
Female
Humans
Male
Medical research
Medical sciences
Medications Development
Middle Aged
Psychiatric Status Rating Scales - statistics & numerical data
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Quality of Life
Quetiapine
Quetiapine Fumarate
Seroquel
Sleep - drug effects
Substance abuse treatment
Toxicology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background:  Despite advances in developing medications to treat alcohol dependence, few such medications have been approved by the Food and Drug Administration. Identified molecular targets are encouraging and can lead to the development and testing of new compounds. Atypical antipsychotic medications have been explored with varying results. Prior research suggests that the antipsychotic quetiapine may be beneficial in an alcohol‐dependent population of very heavy drinkers. Methods:  In this double‐blind, placebo‐controlled trial, 224 alcohol‐dependent patients who reported very heavy drinking were recruited across 5 clinical sites. Patients received either quetiapine or placebo and Medical Management behavioral intervention. Patients were stratified on gender, clinical site, and reduction in drinking prior to randomization. Results:  No differences between the quetiapine and placebo groups were detected in the primary outcome, percentage heavy‐drinking days, or other drinking outcomes. Quetiapine significantly reduced depressive symptoms and improved sleep but had no effect on other nondrinking outcomes. Results from a subgroup analysis suggest that patients who reduced their drinking prior to randomization had significantly better drinking outcomes during the maintenance phase (p 
ISSN:0145-6008
1530-0277
DOI:10.1111/j.1530-0277.2011.01649.x